Question special
Lead Moderator

To continue discussion on effects of Liraglutide seen during the trial, I was wondering if the panel could comment on the increase in resting pulse observed in patients on Liraglutide. It would be unclear whether this is significant particularly when other cardiometabolic risk factors such as blood pressure, waist circumference and lipid profile have improved. What is the relevance of this signal seen in this class drug? Is it more pronounced with the higher dose of Liraglutide?